Clinical Guidelines Alerts (Oct 22) Banner Image
  • Drug Allergy (2022 Update)
    • Society:American College of Allergy, Asthma, & Immunology (ACAAI) & American Academy of Allergy, Asthma, & Immunology (AAAI)
    • Published:October 3, 2022

Breast Cancer Awareness Month

October 2022 

The Latest ClinicalGuidelines & FDA Approvals for Breast Cancer

FDA Drug Approvals (Oct 22) Banner Image
  • Trogarzo (Theratechnologies)
    • For administration by intravenous (IV) push, treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant virus failing their current ARV regimen.
  • Oxlumo (Alnylam)
    • Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients.
  • Furoscix (scPharmaceuticals)
    • At-Home Treatment of Congestion Due to Fluid Overload in Chronic Heart Failure.
  • Boostrix (GlaxoSmithKline)
    • For immunization during the third trimester of pregnancy to prevent pertussis (whooping cough) in infants younger than two months of age.
  • Rinvoq (AbbVie)
    • For adults with nonradiographic axial spondyloarthritis (nr-axSpA) who have objective signs of inflammation and who have had an inadequate response to or are intolerant of one or more tumor necrosis factor (TNF) inhibitors.
  • Imjudo (AstraZeneca)
    • Immunotherapy combination for use in the treatment of unresectable hepatocellular carcinoma (HCC).
  • Tecvayli (Janssen)
    • For adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Exclusive Society Guidelines & Many More! 

Search, bookmark, add notes & create

your personal clinical guideline library with your digital copy or one of

our society & specialty subscription bundles

Copyright © 2022 Guideline Central, All rights reserved.